1 Eligibility criteria included (
1) subjects exposed to trauma
2 Eligibility criteria included:
1) residence in defined zip co
3 Eligibility criteria included a body mass index (BMI; in kg/m
4 Eligibility criteria included a diagnosis of RS or secondary
5 Eligibility criteria included a distance control score of 2 o
6 Eligibility criteria included a prostate-specific antigen (PS
7 Eligibility criteria included a recently diagnosed adenoma an
8 Other
eligibility criteria included adequate organ function and goo
9 Eligibility criteria included advanced CRC that had progresse
10 Eligibility criteria included age 18 years or older and takin
11 Patient
eligibility criteria included age 18 years or older, Eastern
12 Eligibility criteria included age 2 to 17 years, AD diagnosis
13 Eligibility criteria included age at least 18 years, centrall
14 Eligibility criteria included age of 6 to 18 years, a forced
15 Eligibility criteria included age older than 18 years and no
16 Eligibility criteria included age older than 18 years, receiv
17 Eligibility criteria included age>6.0 yr, FEV1>or=40% predict
18 Eligibility criteria included all studies reporting on the pr
19 Eligibility criteria included an age of 18 years or older, sm
20 Eligibility criteria included an age of 2-25 y, progressive d
21 Eligibility criteria included any published English-language
22 Eligibility criteria included assessment of macronutrient qua
23 Eligibility criteria included at least one radiologically con
24 Additional
eligibility criteria included disease duration of 2-10 years
25 Key
eligibility criteria included evaluable disease, Eastern Coop
26 Principal
eligibility criteria included exacerbation in corneal stainin
27 Patient
eligibility criteria included GEP primary, Ki-67 of 20% or le
28 Patient
eligibility criteria included having been treated with three
29 Eligibility criteria included histologically confirmed HPV-po
30 Eligibility criteria included inadequate response to or intol
31 Eligibility criteria included measurable disease, 1-3 prior r
32 Key
eligibility criteria included measurable disease, failure of
33 Eligibility criteria included no history of genital warts or
34 Key
eligibility criteria included no history of virological failu
35 Key
eligibility criteria included no history of virological failu
36 Eligibility criteria included observational studies reporting
37 Eligibility criteria included patients who received a diagnos
38 Eligibility criteria included patients with a previously or n
39 Eligibility criteria included patients with p16-positive orop
40 Eligibility criteria included patients with relapsed/refracto
41 Patients and Materials Study
eligibility criteria included patients with stage II to III N
42 Eligibility criteria included presence of measurable disease
43 Eligibility criteria included previous normal vision for >/=1
44 Eligibility criteria included regularly scheduled blood trans
45 Eligibility criteria included resectable stage I to III cance
46 Eligibility criteria included screening HIV RNA concentration
47 Eligibility criteria included stage IV or locally advanced st
48 Eligibility criteria included studies evaluating graft thickn
49 Eligibility criteria included T3-T4N0M0 or T1-T4N1M0 esophage
50 Eligibility criteria included WHO performance status 0 or 1,